---
title: "PRQR.US (PRQR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PRQR.US/news.md"
symbol: "PRQR.US"
name: "PRQR.US"
parent: "https://longbridge.com/en/quote/PRQR.US.md"
datetime: "2026-03-15T01:26:13.356Z"
locales:
  - [en](https://longbridge.com/en/quote/PRQR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PRQR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PRQR.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/PRQR.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/PRQR.US/news.md)


# PRQR.US (PRQR.US) — Related News

### [ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty](https://longbridge.com/en/news/278990351.md)
*2026-03-13T06:01:00.000Z*
> ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty

### [Chardan Capital Keeps Their Buy Rating on ProQR (PRQR)](https://longbridge.com/en/news/278958185.md)
*2026-03-12T23:55:36.000Z*
> Chardan Capital analyst Keay Nakae has maintained a Buy rating on ProQR (PRQR) with a price target of $4.00. Nakae, a 4-

### [ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer](https://longbridge.com/en/news/278903232.md)
*2026-03-12T14:31:29.000Z*
> Oppenheimer has initiated coverage on ProQR Therapeutics (NASDAQ:PRQR), assigning an "outperform" rating and a price tar

### [ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 47.2% in January](https://longbridge.com/en/news/275981002.md)
*2026-02-14T13:39:20.000Z*
> ProQR Therapeutics N.V. (NASDAQ:PRQR) experienced a significant increase in short interest of 47.2% in January, totaling

### [ProQR Therapeutics NV Announces Departure of Board Members Dinko Valerio and Alison Lawton](https://longbridge.com/en/news/275320171.md)
*2026-02-09T13:00:26.000Z*
### [Proqr Announces Encouraging Ax-0810 Phase 1](https://longbridge.com/en/news/271942142.md)
*2026-01-08T13:39:04.000Z*
### [ProQR Reports Positive Initial Safety Data from AX-0810 Phase 1 Trial](https://longbridge.com/en/news/271936108.md)
*2026-01-08T13:01:09.000Z*